Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Office Of Drug Safety In Transition; Director Raczkowski Joins Cephalon

Executive Summary

Former FDA Office of Drug Safety Director Victor Raczkowski, MD, is joining Cephalon as VP-regulatory affairs

Related Content

FDA Gets Permanent Drug Safety Director In Advance Of Drug Center Overhaul
FDA Office Of Drug Safety Director Could Be Named By Late Summer
FDA Office Of Drug Safety Acting Director Is Ralph Lillie
IoM Drug Safety Study May Buy Time For FDA; Report Will Play In PDUFA IV
FDA Drug Safety Office Is “Separate, But Unequal,” Senate Committee Says
FDA Handling Of Antidepressant Inquiry “Troubles” Senate Investigators
FDA Office Of Drug Safety Gets Two Permanent Division Directors
FDA Drug Safety Upgrades Coming; Medicare Bill Could Help Win Funding
CDER Deputy Galson Will Run Drug Center For At Least Six Months
FDA Office Of Drug Safety Director-Designate Is ODE III Deputy Raczkowski



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts